Logo

Invitrogen Shares Gain 5.7 Percent on Zymed Acquisition News

Jan 10, 2005

NEW YORK, Jan. 10 (GenomeWeb News) - Shares in Invitrogen were up 5.74 percent, or $3.70, at $68.18 in mid-afternoon trading after the company said it plans to acquire antibody manufacturer Zymed Laboratories.

 

As GenomeWeb News reported this morning, Zymed, based in South San Francisco, Calif., sells immunoassay reagents for research and clinical diagnostics. The company has more than 2,000 antibodies and related products suitable for research in the areas of cancer, neurological diseases, and infectious disease.

 

Following the acquisition, which Invitrogen said it will close for $60 million in cash around the end of February, Zymed's South San Franciscofacility will become the main site for Invitrogen's antibody production and distribution.

 

Invitrogen expects Zymed to generate $15 million in sales during the first year following the acquisition.

Breaking News
The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.